Literature DB >> 29602397

A Systems-Level View of Renal Metabolomics.

Eugene P Rhee1.   

Abstract

The measurement of select circulating metabolites such as creatinine, glucose, and cholesterol are integral to clinical medicine, with implications for diagnosis, prognosis, and treatment. Metabolomics studies in nephrology research seek to build on this paradigm, with the goal to identify novel markers and causal participants in the pathogenesis of kidney disease and its complications. This article reviews three themes pertinent to this goal. Each is rooted in long-established principles of human physiology, with recent updates enabled by metabolomics and other tools. First, the kidney has a broad and heterogeneous impact on circulating metabolites, with progressive loss of kidney function resulting in a multitude of small molecule alterations. Second, an increasing number of circulating metabolites have been shown to possess functional roles, in some cases acting as ligands for specific G-protein-coupled receptors. Third, circulating metabolites traffic through varied, and sometimes complex, interorgan circuits. Taken together, these themes emphasize the importance of viewing renal metabolomics at the systems level, recognizing the diverse origins and physiologic effects of blood metabolites. However, how to synthesize these themes and how to establish clinical relevance remain uncertain and will require further investigation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Metabolomics; metabolism; systems biology

Mesh:

Substances:

Year:  2018        PMID: 29602397      PMCID: PMC5880322          DOI: 10.1016/j.semnephrol.2018.01.005

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  66 in total

Review 1.  Renal metabolism of amino acids: its role in interorgan amino acid exchange.

Authors:  Marcel C G van de Poll; Peter B Soeters; Nicolaas E P Deutz; Kenneth C H Fearon; Cornelis H C Dejong
Journal:  Am J Clin Nutr       Date:  2004-02       Impact factor: 7.045

Review 2.  Proteomics and metabolomics as tools to unravel novel culprits and mechanisms of uremic toxicity: instrument or hype?

Authors:  William Mullen; Daisuke Saigusa; Takaaki Abe; Jerzy Adamski; Harald Mischak
Journal:  Semin Nephrol       Date:  2014-02-18       Impact factor: 5.299

Review 3.  Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Clin Exp Nephrol       Date:  2011-05-25       Impact factor: 2.801

Review 4.  Mendelian Randomization as an Approach to Assess Causality Using Observational Data.

Authors:  Peggy Sekula; Fabiola Del Greco M; Cristian Pattaro; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2016-08-02       Impact factor: 10.121

5.  Plasma metabolomic profiles in different stages of CKD.

Authors:  Vallabh O Shah; Raymond R Townsend; Harold I Feldman; Kirk L Pappan; Elizabeth Kensicki; David L Vander Jagt
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

Review 6.  Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM).

Authors:  Juan Jesús Carrero; Peter Stenvinkel; Lilian Cuppari; T Alp Ikizler; Kamyar Kalantar-Zadeh; George Kaysen; William E Mitch; S Russ Price; Christoph Wanner; Angela Y M Wang; Pieter ter Wee; Harold A Franch
Journal:  J Ren Nutr       Date:  2013-03       Impact factor: 3.655

Review 7.  Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications.

Authors:  J E Gerich
Journal:  Diabet Med       Date:  2010-02       Impact factor: 4.359

Review 8.  Mendelian randomization studies in coronary artery disease.

Authors:  Henning Jansen; Nilesh J Samani; Heribert Schunkert
Journal:  Eur Heart J       Date:  2014-06-10       Impact factor: 29.983

9.  A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients.

Authors:  Sahir Kalim; Clary B Clish; Julia Wenger; Sammy Elmariah; Robert W Yeh; Joseph J Deferio; Kerry Pierce; Amy Deik; Robert E Gerszten; Ravi Thadhani; Eugene P Rhee
Journal:  J Am Heart Assoc       Date:  2013-12-05       Impact factor: 5.501

10.  Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study.

Authors:  Monika A Niewczas; Tammy L Sirich; Anna V Mathew; Jan Skupien; Robert P Mohney; James H Warram; Adam Smiles; Xiaoping Huang; Walker Walker; Jaeman Byun; Edward D Karoly; Elizabeth M Kensicki; Gerard T Berry; Joseph V Bonventre; Subramaniam Pennathur; Timothy W Meyer; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2014-01-15       Impact factor: 10.612

View more
  4 in total

1.  Genome-wide association study of serum metabolites in the African American Study of Kidney Disease and Hypertension.

Authors:  Shengyuan Luo; Elena V Feofanova; Adrienne Tin; Sarah Tung; Eugene P Rhee; Josef Coresh; Dan E Arking; Aditya Surapaneni; Pascal Schlosser; Yong Li; Anna Köttgen; Bing Yu; Morgan E Grams
Journal:  Kidney Int       Date:  2021-04-08       Impact factor: 18.998

2.  The relationship between blood metabolites of the tryptophan pathway and kidney function: a bidirectional Mendelian randomization analysis.

Authors:  Yurong Cheng; Yong Li; Paula Benkowitz; Claudia Lamina; Anna Köttgen; Peggy Sekula
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 3.  Uncovering Molecular Heterogeneity in the Kidney With Spatially Targeted Mass Spectrometry.

Authors:  Angela R S Kruse; Jeffrey M Spraggins
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566

4.  A Specific Urinary Amino Acid Profile Characterizes People with Kidney Stones.

Authors:  Aniello Primiano; Silvia Persichilli; Pietro Manuel Ferraro; Riccardo Calvani; Alessandra Biancolillo; Federico Marini; Anna Picca; Emanuele Marzetti; Andrea Urbani; Jacopo Gervasoni
Journal:  Dis Markers       Date:  2020-06-30       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.